### GARDP’s pipeline (April 2022)

<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>DISEASE AREA</th>
<th>TRANSLATIONAL</th>
<th>DEVELOPMENT</th>
<th>REGULATORY</th>
<th>IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMR Screening Consortium</td>
<td>SERIOUS BACTERIAL INFECTIONS</td>
<td>Pre-clinical / Early Clinical</td>
<td>Pediatric trials</td>
<td>Cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals**</td>
<td>Access strategy</td>
</tr>
<tr>
<td>Antibiotic potentiators</td>
<td></td>
<td></td>
<td></td>
<td>Cefiderocol*** Neonatal PIP / PSP</td>
<td></td>
</tr>
<tr>
<td>Natural Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Access opportunity</td>
</tr>
<tr>
<td>HIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Potential pipeline addition, MOU signed between GARDP, Shionogi and Clinton Health Access Initiative (CHAI) to explore Cefiderocol access in LMICs**

### Potential Candidate A (NCE or repurposed)
- **Paediatric cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals**
- Polymyxin B*
- Flomoxef
- Amikacin
- IV Fosfomycin

### Regulatory paediatric plans (serious bacterial infections, paediatric and neonates)
- Public health strategic efficacy and safety trials
- Surveillance / Prevalence studies

### Approval
- Approved in EU, with Neo & Paeds label
- Approved in Asia: Neo & Paeds data
- Approved globally: Neo & Paeds data
- Approved in USA, with limited Neo & Paeds label

### Access Development
- Access strategy
- Access opportunity

---

* Under review / on-hold
** Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Welcome Trust in the United Kingdom
*** Potential pipeline addition, MOU signed between GARDP, Shionogi and Clinton Health Access Initiative (CHAI) to explore Cefiderocol access in LMICs